Portfolio of Genomics Stocks

Genomics includes agrigenomics, bacterial genomics, bioinformatics, cancer genomics, diagnostics, drug discovery, equipment, pharmacogenomics and research.

Here is a table of 11 genomics stocks.


11 Genomics Stocks

Stock Returns & Price Chart

Symbol

Recent Prices &
Annualized Return

Agilent TechnologiesA
Alnylam PharmaceuticalsALNY
CRISPR TherapeuticsCRSP
Editas MedicineEDIT
Exact SciencesEXAS
IlluminaILMN
Ionis PharmaceuticalsIONS
Myriad GeneticsMYGN
QIAGEN N.V.QGEN
Sangamo TherapeuticsSGMO
Spark TherapeuticsONCE
Price data from Quandl as of most recent close.


11 Genomics Stocks

Stock Returns & Price Chart

Symbol

Recent Dividends

Agilent TechnologiesA
Alnylam PharmaceuticalsALNY
CRISPR TherapeuticsCRSP
Editas MedicineEDIT
Exact SciencesEXAS
IlluminaILMN
Ionis PharmaceuticalsIONS
Myriad GeneticsMYGN
QIAGEN N.V.QGEN
Sangamo TherapeuticsSGMO
Spark TherapeuticsONCE
Dividend chart data from Quandl as of today.


To inspect the performance of the Genomics Stocks portfolio, see the chart below. Portfolio values are computed using monthly closes for stocks from Quandl.

The 7 stocks included in the portfolio computations are: A, ALNY, EXAS, ILMN, MYGN, QGEN and SGMO. The current value of the portfolio assumes that $1,428.57 was invested (total of $10,000) in each stock at its closing monthly price for the first date shown on the portfolio value chart below. All prices are adjusted for splits and dividends. The 4 stocks excluded from the portfolio computations because of insufficient price data are: CRSP, EDIT, IONS and ONCE.

The current value of a $10,000 investment is $81,460. The percent return is 714.60%. The annualized return is 23.34%.




Return Summary for Genomics Stocks
Start DateNov-30-2009
Start Investment$10,000.00
End DateNov-18-2019
Current Value of Investment$81,460.14
Total Return714.60%
Annualized Return23.34%
Min DateNov-30-2009
Min Price$10,000.00
Max DateJun-28-2019
Max Price$102,720.55
# Values121
Number Returns7,260
Number Profitable Returns6,529
Percent Profitable Returns89.93%
Number Unprofitable Returns731
Percent Unprofitable Returns10.07%
Profitable to Unprofitable Returns Ratio8.93



NOTE: The stocks included in the tables and chart are representative of the industry. They are not recommendations.


Related Portfolios

Portfolio of Gene Editing (CRISPR) Stocks

Portfolio of Genetic Testing Stocks

Portfolio of Stem Cell Stocks